Background: Obesity is responsible for high morbidity and mortality, both in developed and developing countries. It is associated with many chronic and metabolic diseases. Asymmetric dimethylarginine (ADMA) has been demonstrated to be a biomarker of endothelial dysfunction in humans and increased ADMA associated with cardiovascular disease (CVD) risk has been reported in many states. Neopterin (NP) produced by monocytes/macrophages in response to stimulation by interferon-gamma (IFN-γ) is emphasized in recent findings. The current study aims to investigate ADMA and NP levels which may assume a role in guiding the early diagnosis of coronary artery disease in obesity.
Methods: This is an original research study in which ADMA and NP levels of 50 patients (25 male/25 female) diagnosed with obesity were compared with those of 30 healthy individuals (15 male/15 female) as control. The high-performance liquid chromatography (HPLC) method was used while determining parameters.
Results: ADMA and NP levels in obese individuals were found to be significantly higher than in those enrolled in the control. ADMA values were found to be higher in obese subjects (0.71±0.24 μmol/L) as compared with levels found in healthy subjects (0.58±0.16 μmol/L) (p<0.05). A significant increase of serum neopterin levels was found in obese subjects (8.8±3.5 μmol/L) as compared with controls (4.9±1.69 μmol/L) (p<0.05). Also, there was a strong positive correlation between NP and ADMA values in obese individuals (r=0.954).
Conclusions: Our study revealed that obese subjects have higher ADMA and neopterin levels. These results demonstrated that both ADMA and NP levels may be potential risk factors for coronary heart disease in obesity.
Uvod: Gojaznost je odgovorna je za visoki morbiditet i mortalitet, kako u razvijenim zemljama tako i u zemljama u razvoju. Povezana je sa mnogim hroničnim bolestima i bolestima metabolizma. Dokazano je da je asimetrični dimetilaginin (ADMA) biomarker endotelne disfunkcije kod ljudi, a u mnogim državama je uočeno da je povećan ADMA povezan sa rizikom od kardiovaskularnih bolesti (CVD) prijavljen je u mnogim državama. U mnogim istraživanjima skorijeg datuma ukazano je na neopterin (NP) proizveden monocitima/makrofazima kao odgovor na stimulaciju interferon-gama (IFN-γ). Cilj ove studije je da se ispita nivo ADMA i NP koji mogu biti smernica za ranu dijagnoze bolesti koronarnih arterija kod gojaznih pacijenata.
Metode: Ovo je originalna istraživačka studija u kojoj su upoređeni nivoi ADMA i NP kod 50 pacijenata (25 muškaraca/25 žena) kojima je dijagnostikovana gojaznost sa istim vrednostima kod 30 zdravih pojedinaca (kontrolna grupa od 15 muškaraca/15 žena). Pri određivanju parametara korišćena je metoda tečne hromatografije visokih performansi (HPLC).
Rezultati: Utvrđeno je da su nivoi ADMA i NP kod gojaznih pojedinaca značajno viši od onih utvrđenih kod pojedinaca iz kontrolne grupe. Otkriveno je da su vrednosti ADMA veće kod gojaznih ispitanika (0,71 ± 0,24 mmol/L) u poređenju sa vrednostima kod zdravih ispitanika (0,58 ± 0,16 mmol/L) (p < 0,05). Utvrđeno je značajno povećanje nivoa neopterina u serumu kod gojaznih ispitanika (8,8 ± 3,5 mmol/L) u poređenju sa kontrolnom grupom (4,9 ± 1,69 mmol/L) (p < 0,05). Takođe, utvrđena je visoka pozitivna korelacija između vrednosti NP i ADMA kod gojaznih pojedinaca (r = 0,954).
Zaključak: Naše istraživanje je otkrilo da gojazni ispitanici imaju viši nivo ADMA i neopterina. Ovi rezultati su pokazali da i ADMA i NP nivoi mogu biti potencijalni faktori rizika za koronarnu bolest srca kod gojaznih pacijenata.
Keywords: asymmetric dimethylarginine; endothelial dysfunction; neopterin; obesity.
2020 Emre Avci, Alpaslan Karabulut, Avci Gulcin Alp, Burcu Baba, Cumhur Bilgi, published by CEON/CEES.